Information Provided By: 
Fly News Breaks for December 16, 2019
CRSP
Dec 16, 2019 | 13:34 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $104 price target on Crispr Therapeutics (CRSP) after the company completed the consolidation of the Casebia joint venture. The analyst added that Crispr and partner Vertex (VRTX) recently reported first-ever CTX001 data showing potentially curative effect in one beta thalassemia and one sickle cell disease patient, saying he anticipates updated data next year and could see accelerated approval based on only a few patients.
News For CRSP From the Last 2 Days
CRSP
Apr 23, 2024 | 08:08 EDT
Meeting to be held in San Francisco on April 24 hosted by Mizuho.
